367
Participants
Start Date
March 17, 2017
Primary Completion Date
January 20, 2022
Study Completion Date
October 17, 2022
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Cisplatin
Specified dose on specified days
Carboplatin
Specified dose on specified days
Local Institution - 0027, Hong Kong
Local Institution - 0023, Taipei
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution - 0021, Tainan City
Local Institution, Tainan City
Local Institution, Kaohsiung City
Local Institution, Taipei
Local Institution - 0064, New York
Local Institution, Gyeonggi-do
Local Institution - 0066, Taipei
Local Institution - 0108, Taipei
Local Institution, Marseille
Fox Chase Cancer Center, Philadelphia
Johns Hopkins University, Baltimore
Local Institution, Madrid
Local Institution, Majadahonda
Local Institution, Málaga
Local Institution, Toulouse
Local Institution, Rennes
Local Institution - 0018, Taichung
Local Institution, Taichung
Local Institution, Zaragoza
Local Institution - 0004, Chicago
Local Institution - 0045, Chiayi City
Local Institution - 0156, Paris
Local Institution - 0063, Tyler
Texas Health Physicians Group, Arlington
Baylor Scott and White Research Institute, Temple
Local Institution, Kaohsiung City
Local Institution - 0019, Kaohsiung City
Local Institution - 0001, Salt Lake City
Local Institution - 0029, Los Angeles
Local Institution - 0033, Los Angeles
Torrance Memorial Physican Network, Redondo Beach
Pacific Shores Medical Group, Long Beach
Local Institution - 0061, Orange
Local Institution, Beijing
Local Institution, Beijing
Local Institution - 0042, Singapore
Local Institution, Changchun
Local Institution, Changchun
Local Institution, Shanghai
Local Institution, Shanghai
Local Institution - 0041, Singapore
Local Institution - 0016, Hangzhou
Local Institution - 0017, Hangzhou
Local Institution, Hangzhou
Local Institution, Chongqing
Local Institution - 0043, Changsha
Local Institution, Zhengzhou
Local Institution, Guangzhou
Local Institution, Chengdu
Local Institution, Xi'an
Local Institution, Bunkyō City
Local Institution - 0078, Koto-ku
Local Institution - 0079, Tokyo
Local Institution - 0081, Yokohama
Local Institution, Chiba
Local Institution, Nagoya
Local Institution, Kishiwada Shi
Local Institution, Wakayama
Local Institution, Kobe
Local Institution - 0097, Itami
Local Institution, Himeji-shi
Local Institution, Fukuyama
Local Institution, Hiroshima
Local Institution, Ube Shi
Local Institution, Iizuka
Local Institution, Fukushima
Local Institution, Kōriyama
Local Institution - 0077, Sendai
Local Institution - 0003, New Haven
Local Institution - 0002, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Duke University Medical Center, Butner
Local Institution - 0166, Edmonton
Local Institution - 0168, Montreal
Local Institution, Hong Kong
Local Institution - 0024, Hong Kong
Local Institution, Shatin
Local Institution, Hirosaki-shi
Local Institution, Matsuyama
Local Institution - 0059, Kurume
Local Institution - 0070, Sapporo
Local Institution, Yokohama
Local Institution, Yokohama
Local Institution, Kumamoto
Local Institution, Natori-shi
Local Institution, Hirakata-shi
Local Institution, Sakai
Local Institution - 0058, Sayama
Local Institution - 0076, Hidaka
Local Institution, Kitaadachi-gun
Local Institution - 0069, Chūō
Local Institution, Fukuoka
Local Institution, Fukuoka
Local Institution, Niigata
Local Institution, Toyama
Local Institution - 0038, Seoul
Local Institution - 0037, Seoul
Local Institution - 0035, Seoul
Local Institution, Cheogju-si
Local Institution - 0036, Gyeonggi-do
Local Institution, Inchoen
Local Institution, Seoul
Local Institution - 0158, Barcelona
Local Institution, L'Hospitalet de Llobregat
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY